NASDAQ:IMGN - ImmunoGen Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.50 +0.12 (+1.63 %)
(As of 10/16/2018 06:15 AM ET)
Previous Close$7.38
Today's Range$7.15 - $7.62
52-Week Range$4.80 - $13.41
Volume1.74 million shs
Average Volume2.63 million shs
Market Capitalization$1.41 billion
P/E Ratio-10.00
Dividend YieldN/A
Beta1.96
ImmunoGen, Inc., a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Jazz Pharmaceuticals plc; and Debiopharm International SA. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Receive IMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for IMGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:IMGN
CUSIP45253H10
Phone781-895-0600

Debt

Debt-to-Equity Ratio0.02
Current Ratio5.76
Quick Ratio5.73

Price-To-Earnings

Trailing P/E Ratio-10.00
Forward P/E Ratio-6.30
P/E GrowthN/A

Sales & Book Value

Annual Sales$115.45 million
Price / Sales9.68
Cash FlowN/A
Price / CashN/A
Book Value($0.14) per share
Price / Book-53.57

Profitability

EPS (Most Recent Fiscal Year)($0.75)
Net Income$-96,010,000.00
Net Margins-194.78%
Return on EquityN/A
Return on Assets-43.36%

Miscellaneous

Employees293
Outstanding Shares149,020,000
Market Cap$1.41 billion

ImmunoGen (NASDAQ:IMGN) Frequently Asked Questions

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) posted its quarterly earnings results on Friday, July, 27th. The biotechnology company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.02. The biotechnology company had revenue of $9.29 million for the quarter, compared to analyst estimates of $14.12 million. The business's quarterly revenue was down 76.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.10) EPS. View ImmunoGen's Earnings History.

When is ImmunoGen's next earnings date?

ImmunoGen is scheduled to release their next quarterly earnings announcement on Friday, November 2nd 2018. View Earnings Estimates for ImmunoGen.

How can I listen to ImmunoGen's earnings call?

ImmunoGen will be holding an earnings conference call on Friday, November 2nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

What price target have analysts set for IMGN?

8 analysts have issued 12 month price targets for ImmunoGen's stock. Their predictions range from $5.00 to $20.00. On average, they expect ImmunoGen's share price to reach $14.75 in the next year. This suggests a possible upside of 96.7% from the stock's current price. View Analyst Price Targets for ImmunoGen.

What is the consensus analysts' recommendation for ImmunoGen?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ImmunoGen.

What are Wall Street analysts saying about ImmunoGen stock?

Here are some recent quotes from research analysts about ImmunoGen stock:
  • 1. According to Zacks Investment Research, "ImmunoGen has made significant progress with regard to its lead ovarian cancer candidate, mirvetuximab soravtansine. Successful development and subsequent approval of the candidate will be a huge boost to the company as the ovarian cancer market has immense potential. The company has collaborations with big healthcare companies which not only validate its technology but also provides it with funds in the form of milestone and royalty payments. However, ImmunoGen is heavily dependent on its lead candidate, mirvetuximab soravtansine. Hence, any kind of development or a regulatory setback could hamper the stock. The ovarian cancer space being competitive is also a matter of concern for the company. The company’s shares have outperformed the industry so far this year." (9/24/2018)
  • 2. HC Wainwright analysts commented, "Our 12-month, $18 price target on shares of ImmunoGen is based on a 13-year DCF-driven, sum-of-the-parts analysis. Our DCF analysis is based on: beta of 1.9, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 12.5%, and tax rate of 12% beginning in FY 2028. Note, our $18 price target is leveraged on the outcome of the mirvetuximab soravtansine’s Phase 3 FORWARD I study, which represents approximately 89% of our target (risk-adjusted NPV of $16 per share). Key risks to our valuation include: emergence of ADC-related safety concerns, clinical, regulatory, and financials risks. ImmunoGen, Inc." (7/30/2018)
  • 3. Cantor Fitzgerald analysts commented, "FORWARD Progress. The nearest term commercial opportunity for IMGN is the FORWARD I trial, which is exploring mirvetuximab soravtansine (mirva") as a single agent in 3rd line ovarian cancer in women who express high levels of the FRa receptor. This trial could read out in 2019 pending completion of enrollment in 2018." (11/3/2017)

Who are some of ImmunoGen's key competitors?

Who are ImmunoGen's key executives?

ImmunoGen's management team includes the folowing people:
  • Mr. Mark J. Enyedy, Pres, CEO & Director (Age 54)
  • Mr. David B. Johnston, Exec. VP & CFO (Age 63)
  • Dr. Richard J. Gregory, Exec. VP & Chief Scientific Officer (Age 60)
  • Mr. Craig Barrows, Exec. VP, Gen. Counsel & Sec. (Age 63)
  • Dr. Anna Berkenblit, VP & Chief Medical Officer (Age 48)

How do I buy shares of ImmunoGen?

Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ImmunoGen's stock price today?

One share of IMGN stock can currently be purchased for approximately $7.50.

How big of a company is ImmunoGen?

ImmunoGen has a market capitalization of $1.41 billion and generates $115.45 million in revenue each year. The biotechnology company earns $-96,010,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. ImmunoGen employs 293 workers across the globe.

What is ImmunoGen's official website?

The official website for ImmunoGen is http://www.immunogen.com.

How can I contact ImmunoGen?

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]


MarketBeat Community Rating for ImmunoGen (NASDAQ IMGN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  339 (Vote Outperform)
Underperform Votes:  356 (Vote Underperform)
Total Votes:  695
MarketBeat's community ratings are surveys of what our community members think about ImmunoGen and other stocks. Vote "Outperform" if you believe IMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel